Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15237061 | 0.80 | ALDH1A1 (0.31) | MEN1KMT2A | |
| SCHEMBL967673 | 0.79 | — | — | |
| SCHEMBL16407880 | 0.78 | — | — | |
| SCHEMBL2570923 | 0.76 | TSHR (0.34) | — | |
| SCHEMBL21235988 | 0.75 | — | — | |
| SCHEMBL8275902 | 0.75 | CA2 (0.30) | HTR2AHRH1 | |
| SCHEMBL497965 | 0.74 | — | — | |
| SCHEMBL967670 | 0.74 | — | — | |
| SCHEMBL15114450 | 0.73 | NOS2 (0.32) | MEN1KMT2A | |
| SCHEMBL21450436 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20160272640-A1 | SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-09-22 | — | — | US | disclosed |
| US-7683176-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| EP-0350260-B1 | New oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain | MEIJI SEIKA KAISHA (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-5232947-A | Administering to ameliorate damage from anoxia | MEIJI SEIKA KAISHA, LTD. (JP) | 1993-08-03 | — | — | US | disclosed |
| EP-0350260-A2 | New oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain | MEIJI SEIKA KAISHA LTD. (JP) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039504-A1 | TRIAZOLYL PYRIDYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | MEN1 4866/4885KMT2A 3844/4885PGR 973/4885 |
| US-20160272640-A1 | SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF | OPRD1, OPRL1, P2RX4 | MEN1 4671/4885KMT2A 1361/4885PGR 2110/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | MEN1 1510/4885KMT2A 2461/4885PGR 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.